leadf
logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience agrees to sell non-pharmaceutical THC related assets for 3.85 million

Lexaria Bioscience (CSE: LXX- OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has agreed to sell certain non-core, non-pharmaceutical THC-related business assets to Hill Street Beverage for 3.85 million Canadian.

Bunka also told Proactive “Hill Street is acquiring royalty-free and perpetual global rights including relicensing rights of Lexaria's DehydraTECH technology” He also said Lexaria retains full ownership of its DehydraTECH technology.

Quick facts: Lexaria Bioscience Corp.

Price: 0.255 CAD

CSE:LXX
Market: CSE
Market Cap: $22.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria receives ethics board ok to launch human study with DehydraTech for...

Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus...

on 29/9/20

2 min read